ZEALAND PHARMA/S (NASDAQ:ZEAL) hit a new 52-week high during trading on Thursday . The company traded as high as $41.08 and last traded at $40.76, with a volume of 9187 shares changing hands. The stock had previously closed at $38.50.
A number of research analysts have recently commented on the company. Zacks Investment Research reissued a “hold” rating and set a $41.00 price objective on shares of ZEALAND PHARMA/S in a report on Saturday, January 25th. Morgan Stanley increased their price objective on ZEALAND PHARMA/S from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Jefferies Financial Group lowered ZEALAND PHARMA/S from a “buy” rating to a “hold” rating in a report on Wednesday, November 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of ZEALAND PHARMA/S in a report on Monday, February 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $40.50.
The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -18.44 and a beta of 2.02. The stock has a fifty day moving average price of $36.24 and a 200 day moving average price of $29.00.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.18. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $7.50 million. On average, analysts forecast that ZEALAND PHARMA/S will post -2 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of ZEAL. Jane Street Group LLC boosted its stake in ZEALAND PHARMA/S by 14.2% during the 4th quarter. Jane Street Group LLC now owns 13,634 shares of the company’s stock valued at $482,000 after purchasing an additional 1,692 shares during the period. Renaissance Technologies LLC boosted its stake in ZEALAND PHARMA/S by 163.9% during the 4th quarter. Renaissance Technologies LLC now owns 27,978 shares of the company’s stock valued at $929,000 after purchasing an additional 17,378 shares during the period. Finally, Rockefeller Capital Management L.P. bought a new stake in ZEALAND PHARMA/S during the 4th quarter valued at approximately $324,000. 8.88% of the stock is currently owned by institutional investors and hedge funds.
About ZEALAND PHARMA/S (NASDAQ:ZEAL)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Recommended Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.